Literature DB >> 28745903

Trend of Socio-Demographic Index and Mortality Estimates in Iran and its Neighbors, 1990-2015; Findings of the Global Burden of Diseases 2015 Study.

Maziar Moradi-Lakeh1, Sadaf G Sepanlou2, Seyed M Karimi3, Narjes Khalili1, Shirin Djalalinia4, Chante Karimkhani5, Kristopher Krohn6, Ashkan Afshin6, Farshad Farzadfar7, Aliasghar Ahmad Kiadaliri8, Mohsen Asadi-Lari9, Hamid Asayesh10, Ali Reza Esteghamati11, Maryam S Farvid12, Seyed-Mohammad Fereshtehnejad13, Pouria Heydarpour14, Ardeshir Khosravi15, Jagdish Khubchandani16, Amir Kasaeian17, Saleem M Rana18, Mahdi Mahdavi19, Habib Masoudifarid20, Alireza Mohammadi21, Farshad Pourmalek22, Mostafa Qorbani23, Amir Radfar24, Kazem Rahimi25, Vafa Rahimi-Movaghar26, Gholamreza Roshandel27, Sare Safi28, Payman Salamati26, Arash Tehrani-Banihashemi1, Shahrzad Bazargan-Hejazi29, Theo Vos6, Reza Malekzadeh2, Ali H Mokdad6, Christopher J L Murray6, Mohsen Naghavi6.   

Abstract

BACKGROUND: The Global burden of disease and injuries study (GBD 2015) reports expected measures for years of life lost (YLL) based on socio-demographic index (SDI) of countries, as well as the observed measures. In this extended GBD 2015 report, we reviewed total and cause-specific deaths and YLL for Iran and all its neighboring countries between 1990 and 2015.
METHODS: We extracted data from the GBD 2015 database. Observed YLL measures were calculated by multiplying the number of deaths by standard life expectancy at each age. SDI was a composite index, calculated based on income per capita, average years of schooling, and total fertility rate. The GBD world population was used for age standardization.
RESULTS: All-ages crude death rate in Iran reduced from 665.6 per 100,000 population (95% uncertainty interval: 599.3-731.6) in 1990 to 487.2 (414.9-566.1) in 2015. The ratio of observed to expected YLL (O/E ratio) for all-causes ranged between 0.54 (Turkey) and 1.95 (Russia) in 2015. For Iran, the all-causes O/E ratio was less than 1 in all years (1990-2015), except 2003. However, cause-specific O/E ratio was more than 1 for some causes, including the top leading causes of YLL (ischemic heart disease, road injuries, and cerebrovascular disorders). Ischemic heart disease was the first or second cause of YLL in all comparator countries except Afghanistan.
CONCLUSION: The leading YLL causes with high O/E ratios should be prioritized in public health efforts. In addition to research evidence, countries with low O/E ratios should be scrutinized to find feasible innovative interventions.

Entities:  

Mesh:

Year:  2017        PMID: 28745903

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  4 in total

1.  Temporal Trends of the Incidence of Ischemic Heart Disease in Iran Over 15 Years: A Comprehensive Report from a Multi-Centric Hospital-Based Registry.

Authors:  Fatemeh Nouri; Awat Feizi; Marzieh Taheri; Noushin Mohammadifard; Somayeh Khodarahmi; Masoumeh Sadeghi; Nizal Sarrafzadegan
Journal:  Clin Epidemiol       Date:  2020-08-06       Impact factor: 4.790

2.  Causes of premature death and their associated risk factors in the Golestan Cohort Study, Iran.

Authors:  Mahdi Nalini; Ebele Oranuba; Hossein Poustchi; Sadaf G Sepanlou; Akram Pourshams; Masoud Khoshnia; Abdolsamad Gharavi; Sanford M Dawsey; Christian C Abnet; Paolo Boffetta; Paul Brennan; Masoud Sotoudeh; Arash Nikmanesh; Shahin Merat; Arash Etemadi; Ramin Shakeri; Amir Ali Sohrabpour; Siavosh Nasseri-Moghaddam; Farin Kamangar; Reza Malekzadeh
Journal:  BMJ Open       Date:  2018-07-18       Impact factor: 2.692

3.  Estimating Adult Mortality in Papua New Guinea, 2011.

Authors:  Urarang Kitur; Tim Adair; Alan D Lopez
Journal:  Popul Health Metr       Date:  2019-04-18

4.  Analysis for policy to overcome barriers to reducing the prevalence of vitamin a deficiency among children (15-23 months) in Iran.

Authors:  Golnaz Rajaeieh; Amirhossein Takian; Naser Kalantari; Fatemeh Mohammadi-Nasrabadi
Journal:  BMC Public Health       Date:  2021-06-26       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.